Welcome to our dedicated page for Kardigan news (Ticker: KARD), a resource for investors and traders seeking the latest updates and insights on Kardigan stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kardigan's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kardigan's position in the market.
Kardigan (Nasdaq: KARD), a clinical-stage precision cardiovascular therapeutics company, closed its initial public offering of 28,750,000 common shares, including 3,750,000 from the full underwriters’ option, at $16.00 per share.
Gross proceeds totaled $460 million before underwriting discounts and expenses, and the stock trades on the Nasdaq Global Market as KARD.
Kardigan (Nasdaq: KARD), a clinical-stage precision therapeutics company focused on cardiovascular diseases, priced its upsized IPO of 25,000,000 shares at $16 per share.
Gross proceeds are expected to be $400 million, with trading on the Nasdaq Global Market starting June 18, 2026, and closing expected June 22, 2026.